Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses

NCT ID: NCT00663819

Last Updated: 2018-04-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

258 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this prospective, randomized multicenter center study is to evaluate and compare the outcomes of colorectal, coloanal and ileoanal anastomoses reinforced with a bioabsorbable staple line reinforcement material compared with standard non-reinforced colorectal, coloanal and ileoanal techniques with respect to the incidence of postoperative anastomotic leakage, anastomotic stricture and time to ileostomy closure, if applicable.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized prospective trial that compares the use of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement (CBSG) to standard stapling techniques in colorectal resections. The potential exists to utilize CBSG as a means of lowering the rate of post-operative anastomotic leakage and bleeding in high-risk colorectal, coloanal, and ileoanal anastomoses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Ulcerative Colitis Familial Adenomatous Polyposis Diverticulitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Device

GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers

Group Type ACTIVE_COMPARATOR

GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement

Intervention Type DEVICE

Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler

Procedure/Surgery

Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement

Group Type OTHER

Staple line without reinforcement

Intervention Type PROCEDURE

colorectal and coloanal anastomotic staple line without reinforcement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement

Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler

Intervention Type DEVICE

Staple line without reinforcement

colorectal and coloanal anastomotic staple line without reinforcement

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who will undergo restorative proctectomy or proctocolectomy (\<10 cm from anal verge) with a low circular stapled colorectal, coloanal or ileoanal anastomosis with or without reservoir, including treatment for rectal cancer, ulcerative colitis, familial adenomatous polyposis

, diverticulitis, perforation of the bowel/trauma.
* Subjects undergoing Hartmann's reversal with restorative proctectomy (\<10 cm from the anal verge).
* Subjects may or may not have a diverting loop ileostomy as a component of their initial surgery.
* Subjects who meet the requirements of number 1 and 2, and are being treated for rectal cancer may or may not have preoperative chemoradiation therapy in the treatment of their rectal cancer.

Exclusion Criteria

* Subjects being treated for rectal cancer with a diagnosis of inflammatory bowel disease.
* Subjects who have significant intraoperative hypotension or cardiac events.
* Subjects with collagen vascular disease, coagulopathy, significant renal or hepatic dysfunction (creatinine \>1.6 or liver enzymes \> 50% upper limit of normal values).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

W.L.Gore & Associates

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anthony J Senagore, MD, MBA, MS

Role: PRINCIPAL_INVESTIGATOR

University of Southern California, Keck School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of South Alabama

Mobile, Alabama, United States

Site Status

University of Southern California, Keck School of Medicine

Los Angeles, California, United States

Site Status

University of South Florida-Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Advocate Healthcare/Good Shepard Hospital

Barrington, Illinois, United States

Site Status

John Stroger Hospital of Cook County

Chicago, Illinois, United States

Site Status

Peoria Surgical Group

Peoria, Illinois, United States

Site Status

Colon and Rectal Surgery-NEICRS Group

Fort Wayne, Indiana, United States

Site Status

Kenderick Regional Center

Indianapolis, Indiana, United States

Site Status

Spectrum Health -Ferguson Group

Grand Rapids, Michigan, United States

Site Status

Duluth Clinic

Duluth, Minnesota, United States

Site Status

Albany Medical College

Albany, New York, United States

Site Status

St. Lukes-Roosevelt Hospital Center

New York, New York, United States

Site Status

New York Presbyterian Hospital

New York, New York, United States

Site Status

University Hospitals of Cleveland, Case Medical Center

Cleveland, Ohio, United States

Site Status

Texas Endosurgery Institute

San Antonio, Texas, United States

Site Status

University of Utah Health Sciences Center and Huntsman Cancer Hospital

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CS150

Identifier Type: OTHER

Identifier Source: secondary_id

2008-109

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Seal-G / Seal-G MIST Study
NCT04532515 COMPLETED NA
Safe Anastomosis Feasibility Study
NCT05180565 COMPLETED NA